Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Iodomethane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodomethane SCHEMBL28292214 | 1.00 | — | — | |
| Iodomethane SCHEMBL3666965 | 0.89 | — | — | |
| Iodomethane SCHEMBL27701167 | 0.89 | — | — | |
| Iodomethane SCHEMBL12143615 | 0.87 | — | — | |
| Iodomethane SCHEMBL11184727 | 0.87 | — | — | |
| Iodomethane SCHEMBL13098007 | 0.87 | — | — | |
| Iodomethane SCHEMBL498 | 0.87 | — | — | |
| Iodomethane SCHEMBL384331 | 0.87 | — | — | |
| Iodomethane SCHEMBL2757578 | 0.87 | — | — | |
| Iodomethane SCHEMBL27662698 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| CN-109232362-B | Aromatic heterocyclic derivative and application thereof in medicines | 广东东阳光药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| CN-109232362-A | Aromatic heterocyclic derivatives and its application on drug | 广东东阳光药业有限公司 | 2019-01-18 | — | — | CN | disclosed |
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| CN-1796351-A | Method for preparing desmosdumotin, and application of anti tumour and AIDS | WU JIUHONG (CN) | 2006-07-05 | — | — | CN | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| US-6355840-B1 | REACTION OF TRIALKYLALUMINUM, A METHYLBORANE AND METHYL IODIDE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-03-12 | — | — | US | disclosed |
| US-5731352-A | THERAPY FOR DISORDERS OF THE MELATONINERGIC SYSTEM | ADIR ET COMPAGNIE (FR) | 1998-03-24 | — | — | US | disclosed |
| US-5674863-A | BENZODIAZEPINEDIONE DERIVATIVE; FIBRINOGIN BINDING INHIBITOR | GENENTECH, INC. (US) | 1997-10-07 | — | — | US | disclosed |
| US-5674865-A | BENZODIAZEPINEDIONE DERIVATIVE; FIBRINOGIN BINDING INHIBITOR | GENENTECH, INC. (US) | 1997-10-07 | — | — | US | disclosed |
| US-5663166-A | ANTICOAGULANTS OF 1,4-BENZODIAZEPINE-2,5-DIONE AND 2-BENZOAZEPINE-1,4-DIONE DERIVATIVES; PREVENTS FIBRINOGEN BINDING NECESSARY FOR PLATELET AGGREGATION; SIDE EFFECT REDUCTION, E.G. EXCESSIVE BLEEDING | GENENTECH, INC. (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0775140-A1 | SPIRO-SUBSTITUTED AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1997-05-28 | — | — | EP | disclosed |
| US-5565449-A | PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996005203-A1 | SPIRO-SUBSTITUTED AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
| EP-0610334-B1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII B III A RECEPTOR | GENENTECH INC (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0610334-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII b?III a? RECEPTOR. | GENENTECH INC (US) | 1994-08-17 | — | — | EP | disclosed |
| WO-1993008174-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPIIbIIIa RECEPTOR | GENENTECH, INC. (US) | 1993-04-29 | — | — | WO | disclosed |